|
US5461081A
(en)
*
|
1989-09-28 |
1995-10-24 |
Alcon Laboratories, Inc. |
Topical ophthalmic pharmaceutical vehicles
|
|
US5521222A
(en)
*
|
1989-09-28 |
1996-05-28 |
Alcon Laboratories, Inc. |
Topical ophthalmic pharmaceutical vehicles
|
|
US5932572A
(en)
*
|
1992-02-21 |
1999-08-03 |
Alcon Laboratories, Inc. |
Topical anti-glaucoma compositions
|
|
WO1993016701A2
(en)
*
|
1992-02-21 |
1993-09-02 |
Alcon Laboratories, Inc. |
Topical antiglaucoma compositions comprising carbonic anhydrase inhibitors and beta-blockers
|
|
JPH08501303A
(ja)
*
|
1992-09-17 |
1996-02-13 |
アルコン ラボラトリーズ，インコーポレイテッド |
局所用炭酸脱水酵素阻害剤組成物
|
|
SE9301877D0
(sv)
*
|
1993-06-02 |
1993-06-02 |
Kabi Pharmacia Ab |
In situ gel for therapeutic use
|
|
CN1129400A
(zh)
*
|
1994-05-06 |
1996-08-21 |
阿尔康实验室公司 |
维生素e生育酚衍生物在眼科组合物中的应用
|
|
US6172054B1
(en)
|
1995-06-15 |
2001-01-09 |
Alcon Laboratories, Inc. |
Combination therapy for lowering and controlling intraocular pressure
|
|
US5696166A
(en)
*
|
1995-10-31 |
1997-12-09 |
Yanni; John M. |
Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
|
|
EP0861079A1
(en)
*
|
1995-11-17 |
1998-09-02 |
Alcon Laboratories, Inc. |
Combination therapy for treating glaucoma
|
|
US6441047B2
(en)
|
1995-11-17 |
2002-08-27 |
Alcon Manufacturing Ltd.. |
Combination therapy for treating glaucoma
|
|
FR2754712B1
(fr)
|
1996-10-17 |
1999-09-03 |
Merck Sharp Dohme Chibret Lab |
Compositions ophtalmiques
|
|
CH690814A5
(it)
*
|
1996-11-04 |
2001-01-31 |
Applied Pharma Res |
Composizioni per uso topico contenenti polisaccaridi solfati.
|
|
ZA989513B
(en)
|
1997-10-21 |
1999-04-21 |
Alcon Lab Inc |
Compositions containing histamine H2 agonists and methods of use in treating dry eye
|
|
US6261547B1
(en)
|
1998-04-07 |
2001-07-17 |
Alcon Manufacturing, Ltd. |
Gelling ophthalmic compositions containing xanthan gum
|
|
US6174524B1
(en)
|
1999-03-26 |
2001-01-16 |
Alcon Laboratories, Inc. |
Gelling ophthalmic compositions containing xanthan gum
|
|
WO2000038663A2
(en)
|
1998-12-24 |
2000-07-06 |
Alcon Laboratories, Inc. |
Ep4 receptor agonists for treatment of dry eye
|
|
US6462080B1
(en)
|
1998-12-24 |
2002-10-08 |
Alcon Manufacturing, Ltd. |
Prostaglandin E receptor agonists for treatment of dry eye
|
|
DK1155019T3
(da)
*
|
1999-01-25 |
2006-04-18 |
Nat Jewish Med & Res Center |
Substituerede porphyriner og deres terapeutiske anvendelse
|
|
ES2199873T3
(es)
|
1999-11-01 |
2004-03-01 |
Alcon Inc. |
Composiciones farmaceuticas que contienen un farmaco antibiotico de fluoroquinolona y goma xantan.
|
|
US6552084B2
(en)
|
1999-11-09 |
2003-04-22 |
Alcon Universal Ltd. |
Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
|
|
AU1101301A
(en)
|
1999-11-09 |
2001-06-06 |
Alcon Universal Limited |
2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use
|
|
EP1228028B1
(en)
|
1999-11-09 |
2005-08-10 |
Alcon Inc. |
Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders
|
|
AU776258B2
(en)
|
1999-11-09 |
2004-09-02 |
Alcon Inc. |
Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use
|
|
AU1475701A
(en)
|
1999-11-09 |
2001-06-06 |
Alcon Inc. |
Lipoxin A4 and its analogs for the treatment of dry eye
|
|
US6353032B1
(en)
|
1999-11-09 |
2002-03-05 |
Alcon Universal Ltd. |
Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use
|
|
US6458854B2
(en)
|
1999-11-09 |
2002-10-01 |
Alcon Universal Ltd. |
Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use
|
|
CA2386619A1
(en)
|
1999-11-09 |
2001-05-17 |
Alcon, Inc. |
Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
|
|
CA2386333A1
(en)
|
1999-11-09 |
2001-05-17 |
Alcon, Inc. |
3-heteroatom substituted and two carbon homologs 15-hete and methods of use
|
|
US6803385B2
(en)
|
1999-11-09 |
2004-10-12 |
Alcon, Inc. |
Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
|
|
TR200201252T2
(tr)
|
1999-11-09 |
2003-02-21 |
Alcon, Inc. |
15-Hidroksieikosatetraenoik asit ile ilişkili bileşikler ve bunların kullanım yöntemleri
|
|
DE60007548T2
(de)
|
1999-11-09 |
2004-06-17 |
Alcon, Inc. |
Omega kettenmodifizierte hydroxyeicosatetraensäure derivate verwendbar in der behandlung der "trockenes auge" krankheit
|
|
JP2003513950A
(ja)
|
1999-11-09 |
2003-04-15 |
アルコン，インコーポレイテッド |
１５−ヒドロキシエイコサテトラエン酸のベンゼノイド誘導体およびドライアイ障害を処理するのに使用する方法
|
|
WO2001034550A2
(en)
|
1999-11-09 |
2001-05-17 |
Alcon Universal Ltd. |
15-hydroxyeicosatetraenoic acid analogs with enhanced metabolic stability and methods of their use in treating dry eye disorders
|
|
WO2001046134A1
(en)
|
1999-12-22 |
2001-06-28 |
Alcon Universal Ltd. |
6-KETO PROSTAGLANDIN F1α AND ANALOGS FOR TREATING DRY EYE
|
|
DK1305033T3
(da)
|
2000-07-28 |
2005-01-31 |
Alcon Inc |
Farmaceutiske pæaparater indeholdende tobramycin og xanthangummi
|
|
PE20020578A1
(es)
|
2000-10-10 |
2002-08-14 |
Upjohn Co |
Una composicion de antibiotico topico para el tratamiento de infecciones oculares
|
|
WO2002040056A2
(en)
|
2000-11-06 |
2002-05-23 |
Alcon, Inc |
Carrageenan viscoelastics for ocular surgery
|
|
US20030060447A1
(en)
*
|
2002-04-24 |
2003-03-27 |
Mutlu Karakelle |
Non-aspirating transitional viscoelastics for use in surgery
|
|
US7112588B2
(en)
*
|
2001-05-21 |
2006-09-26 |
Alcon, Inc. |
Use of proteasome inhibitors to treat dry eye disorders
|
|
US6740674B2
(en)
|
2001-05-21 |
2004-05-25 |
Alcon, Inc. |
Use of proteasome inhibitors to treat dry eye disorders
|
|
JP2004531560A
(ja)
*
|
2001-05-21 |
2004-10-14 |
アルコン，インコーポレイテッド |
ドライアイ障害を処置する方法
|
|
JP2004527578A
(ja)
|
2001-05-21 |
2004-09-09 |
アルコン，インコーポレイテッド |
ドライアイ障害を処置するためのＮＦ−κＢインヒビターの使用
|
|
US6872382B1
(en)
|
2001-05-21 |
2005-03-29 |
Alcon, Inc. |
Use of selective PDE IV inhibitors to treat dry eye disorders
|
|
EP1439842A4
(en)
*
|
2001-06-01 |
2009-09-02 |
Nat Jewish Med & Res Center |
OXIDANT CAPTAIN FOR THE TREATMENT OF DIABETES OR FOR THE USE IN THE TRANSPLANTATION OR INDUCTION OF IMMUNOTOLERANE
|
|
US6645994B1
(en)
|
2001-06-01 |
2003-11-11 |
Alcon, Inc. |
Method of treating dry eye disorders
|
|
US6750250B1
(en)
|
2001-07-12 |
2004-06-15 |
Alcon, Inc. |
11,12-oxidoarachidonic acid derivatives and methods of their use in treating dry eye disorders
|
|
US20040214754A1
(en)
*
|
2001-10-03 |
2004-10-28 |
Ellis Edward J. |
Ophthalmic preparation containing glycomacropeptide
|
|
US20040220089A1
(en)
*
|
2001-10-03 |
2004-11-04 |
Ellis Edward J. |
Ophthalmic preparation containing glycoprotein
|
|
WO2003039454A2
(en)
*
|
2001-10-23 |
2003-05-15 |
Oklahoma Medical Research Foundation |
Beta-secretase inhibitors and methods of use
|
|
US20060234944A1
(en)
*
|
2001-10-23 |
2006-10-19 |
Oklahoma Medical Reseach Foundation |
Beta-secretase inhibitors and methods of use
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
AU2003218059A1
(en)
*
|
2002-02-22 |
2003-09-09 |
Pharmacia Corporation |
Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
|
|
WO2003072081A1
(en)
*
|
2002-02-22 |
2003-09-04 |
Pharmacia Corporation |
Ophthalmic formulation with gum system
|
|
EP2316459B1
(en)
|
2002-07-29 |
2013-11-06 |
Rigel Pharmaceuticals, Inc. |
2,4-pyrimidinediamine compounds for use in methods of treating or preventing autoimmune diseases
|
|
US8580851B2
(en)
|
2002-08-21 |
2013-11-12 |
Sucampo Ag |
Ophthalmic solution
|
|
US20060217325A1
(en)
*
|
2002-12-20 |
2006-09-28 |
Alcon, Inc. |
Treatment of dry eye restoring 15-lipoxygenase activity to ocular surface cells
|
|
WO2005013996A2
(en)
|
2003-08-07 |
2005-02-17 |
Rigel Pharmaceuticals, Inc. |
2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
|
|
EP1661573B1
(en)
*
|
2003-08-21 |
2013-09-25 |
Sucampo AG |
Ophtalmic composition comprising unoprostone ispopropyl ester and a viscosity agent
|
|
JP2008513495A
(ja)
*
|
2004-09-17 |
2008-05-01 |
コメンティス，インコーポレーテッド |
ベータ−セクレターゼ活性を阻害する二環式化合物およびその使用方法
|
|
JP2008513497A
(ja)
*
|
2004-09-17 |
2008-05-01 |
コメンティス，インコーポレーテッド |
メマプシン２βセクレターゼ活性を阻害するアミノ含有化合物およびその使用方法
|
|
EP1831225A2
(en)
*
|
2004-11-19 |
2007-09-12 |
The Regents of the University of California |
Anti-inflammatory pyrazolopyrimidines
|
|
MX2007012341A
(es)
*
|
2005-04-08 |
2008-02-12 |
Comentis Inc |
Compuestos que inhiben actividad beta-secretasa y metodos de uso de los mismos.
|
|
WO2007098507A2
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
TW200808375A
(en)
|
2006-05-12 |
2008-02-16 |
Otsuka Pharma Co Ltd |
Hydrogel suspension and manufacturing process thereof
|
|
EP2038272B8
(en)
|
2006-06-30 |
2013-10-23 |
Sunesis Pharmaceuticals, Inc. |
Pyridinonyl pdk1 inhibitors
|
|
CA2673137C
(en)
|
2006-11-21 |
2015-02-10 |
Rigel Pharmaceuticals, Inc. |
Prodrug salts of 2,4-pyrimidinediamine compounds and their uses
|
|
KR20080076667A
(ko)
*
|
2007-02-15 |
2008-08-20 |
주식회사 중외제약 |
요변성 약학 조성물
|
|
JP5658031B2
(ja)
|
2007-06-22 |
2015-01-21 |
ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム |
薄膜凍結による安定したサブミクロンのペプチド又はタンパク質粒子の形成
|
|
CA2697166A1
(en)
*
|
2007-07-26 |
2009-01-29 |
Comentis, Inc. |
Isophthalamide derivatives inhibiting betasecretase activity
|
|
KR20100059919A
(ko)
*
|
2007-09-24 |
2010-06-04 |
코멘티스, 인코포레이티드 |
치료를 위한 베타-세크레타제 억제제로서 (3-히드록시-4-아미노-부탄-2일)-3-(2-티아졸-2-일-피롤리딘-1-카르보닐) 벤즈아미드 유도체 및 관련 화합물
|
|
AU2008350907A1
(en)
|
2007-12-11 |
2009-08-27 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
|
|
MX2010009857A
(es)
*
|
2008-03-07 |
2010-12-07 |
Sun Pharma Advanced Res Co Ltd |
Composicion oftalmica.
|
|
US11382895B2
(en)
|
2008-05-23 |
2022-07-12 |
National Jewish Health |
Methods for treating injury associated with exposure to an alkylating species
|
|
WO2010006072A2
(en)
|
2008-07-08 |
2010-01-14 |
The Regents Of The University Of California |
Mtor modulators and uses thereof
|
|
US8618096B2
(en)
*
|
2008-07-21 |
2013-12-31 |
The Regents Of The University Of California |
Prodrug compositions and methods for using the same in treating cancer and malaria
|
|
JP6144873B2
(ja)
|
2008-09-15 |
2017-06-07 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Ｉｒｅ１、ｓｒｃ、及びａｂｌ活性を調節するための方法及び組成物
|
|
JP5815411B2
(ja)
|
2008-12-30 |
2015-11-17 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
ピリミジンジアミンキナーゼ阻害剤
|
|
PE20150621A1
(es)
|
2009-01-23 |
2015-05-07 |
Rigel Pharmaceuticals Inc |
Derivados de 2,4-diamino-pirimidina n2, n4-disustituidos como inhibidores de jak3
|
|
US8236862B2
(en)
*
|
2009-02-06 |
2012-08-07 |
University Of Southern California |
Therapeutic compositions comprising monoterpenes
|
|
US20100216877A1
(en)
*
|
2009-02-20 |
2010-08-26 |
Micro Labs Limited |
Storage Stable Prostaglandin Product
|
|
WO2011017178A1
(en)
|
2009-07-28 |
2011-02-10 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
BR112012003637A2
(pt)
|
2009-08-17 |
2017-04-25 |
Memorial Sloan Kettering Cancer Center |
"compostos de ligação de proteína de choque térmico, composições, e métodos para preparar e usar os mesmos"
|
|
WO2011029043A1
(en)
|
2009-09-04 |
2011-03-10 |
Biogen Idec Ma Inc. |
Heteroaryl btk inhibitors
|
|
PT2473049T
(pt)
|
2009-09-04 |
2019-03-04 |
Sunesis Pharmaceuticals Inc |
Inibidores de tirosina quinase de bruton
|
|
MX353257B
(es)
|
2009-10-06 |
2018-01-05 |
Millennium Pharmaceuticals Inc Star |
Compuestos heterociclicos utiles como inhibidores de proteina cinasa-1 dependiente de 3-fosfoinositido (pdk1).
|
|
WO2011047384A2
(en)
|
2009-10-16 |
2011-04-21 |
The Regents Of The University Of California |
Methods of inhibiting ire1
|
|
PT2493465E
(pt)
|
2009-10-26 |
2014-12-22 |
Sephoris Pharmaceuticals Llc |
Tratamento de queimaduras solares usando analgésicos e anti-histamínicos
|
|
US20130035325A1
(en)
|
2009-11-16 |
2013-02-07 |
The Regents Of The University Of California |
Kinase inhibitors
|
|
WO2011072257A2
(en)
|
2009-12-10 |
2011-06-16 |
The Regents Of The University Of California |
Amyloid binding agents
|
|
CA2828833C
(en)
|
2010-03-03 |
2020-11-03 |
Neonc Technologies Inc. |
Pharmaceutical compositions comprising monoterpenes
|
|
KR20130053404A
(ko)
|
2010-03-30 |
2013-05-23 |
베르선 코포레이션 |
트롬빈 억제제로서의 다중치환된 방향족 화합물
|
|
EP2563771B1
(en)
|
2010-04-24 |
2015-11-25 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
|
PT2598500T
(pt)
|
2010-07-28 |
2021-07-22 |
Rigel Pharmaceuticals Inc |
Composições e métodos para a inibição da via jak
|
|
US20160038600A1
(en)
|
2012-08-03 |
2016-02-11 |
Neonc Technologies Inc. |
Pharmaceutical compositions comprising poh derivatives
|
|
WO2012083178A1
(en)
|
2010-12-17 |
2012-06-21 |
Neo Oncology Inc. |
Methods and devices for using isoperillyl alcohol
|
|
WO2012027693A2
(en)
|
2010-08-27 |
2012-03-01 |
Neonc Technologies Inc. |
Pharmaceutical compositions comprising poh derivatives
|
|
JP5921560B2
(ja)
|
2010-10-28 |
2016-05-24 |
イノクリン ファーマシューティカルズ，インコーポレイテッド |
金属酵素阻害化合物
|
|
EP2632898A4
(en)
|
2010-10-29 |
2014-04-02 |
Biogen Idec Inc |
HETEROCYCLIC TYROSINE KINASE HEMMER
|
|
KR20180039185A
(ko)
|
2010-11-13 |
2018-04-17 |
이노크린 파마슈티컬즈, 인크. |
금속효소 억제제 화합물
|
|
CA2820718A1
(en)
|
2010-12-13 |
2012-06-21 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
|
WO2012112451A1
(en)
|
2011-02-14 |
2012-08-23 |
Allergan, Inc. |
Ester derivatives of bimatoprost compositions and methods
|
|
CN103649028B
(zh)
|
2011-02-25 |
2015-10-14 |
美国政府健康及人类服务部 |
抑制FtsZ蛋白的克利斯汀类似物
|
|
CN109517897A
(zh)
|
2011-04-28 |
2019-03-26 |
南加利福尼亚大学 |
人类髓源抑制性细胞癌症标记
|
|
BR112013029508B1
(pt)
|
2011-05-17 |
2022-05-03 |
Principia Biopharma, Inc. |
Composto, composição farmacêutica, e, uso do referido composto
|
|
US9376438B2
(en)
|
2011-05-17 |
2016-06-28 |
Principia Biopharma, Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
|
KR102027598B1
(ko)
|
2011-05-17 |
2019-10-01 |
프린시피아 바이오파마, 인코퍼레이티드 |
타이로신 키나아제 저해제
|
|
EP2714069A4
(en)
|
2011-05-25 |
2015-06-24 |
Amylin Pharmaceuticals Llc |
LONG-TERM CONJUGATES WITH TWO HORMONES
|
|
AU2012273161B9
(en)
|
2011-06-19 |
2017-07-06 |
Viamet Pharmaceuticals (NC), Inc. |
Metalloenzyme inhibitor compounds
|
|
KR20180095108A
(ko)
|
2011-06-19 |
2018-08-24 |
비아멧 파마슈티컬즈(엔씨), 인코포레이티드 |
금속효소 억제제 화합물
|
|
WO2012177728A1
(en)
|
2011-06-23 |
2012-12-27 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
|
JP6109165B2
(ja)
|
2011-07-01 |
2017-04-05 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
ヘルペスウイルスワクチンおよび使用方法
|
|
WO2013077921A2
(en)
|
2011-09-02 |
2013-05-30 |
The Regents Of The University Of California |
Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
|
|
EP2771341A4
(en)
|
2011-10-28 |
2015-09-23 |
Univ Texas |
NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
|
|
CN104203936B
(zh)
|
2011-12-11 |
2017-04-19 |
威尔金制药有限公司 |
金属酶抑制剂化合物
|
|
BR112014017751B1
(pt)
|
2012-01-20 |
2021-12-07 |
Mycovia Pharmaceuticals, Inc |
Compostos inibidores de metaloenzima, composições compreendendo os ditos compostos e uso dos ditos compostos
|
|
JP6231548B2
(ja)
|
2012-03-23 |
2017-11-15 |
マテオン セラピューティクス， インコーポレイテッド |
カテプシンの阻害のための組成物および方法
|
|
US20150087628A1
(en)
|
2012-04-10 |
2015-03-26 |
The Regents Of The University Of California |
Compositions and methods for treating cancer
|
|
US20130310340A1
(en)
|
2012-05-16 |
2013-11-21 |
Rigel Pharmaceuticals, Inc. |
Method of treating muscular degradation
|
|
WO2013185082A2
(en)
|
2012-06-08 |
2013-12-12 |
Biogen Idec Ma Inc. |
Inhibitors of bruton's tyrosine kinase
|
|
AR091273A1
(es)
|
2012-06-08 |
2015-01-21 |
Biogen Idec Inc |
Inhibidores de pirimidinil tirosina quinasa
|
|
CA2913736A1
(en)
|
2012-06-11 |
2013-12-19 |
The Regents Of The University Of California |
Compounds and methods of treating cancer
|
|
JP6270848B2
(ja)
|
2012-08-27 |
2018-01-31 |
アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ |
ベータ−クロロシクロペンタンの親水性エステルプロドラッグの使用による角膜中央部肥厚の低下
|
|
US9090595B2
(en)
|
2012-08-27 |
2015-07-28 |
Allergan, Inc. |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
|
MX361815B
(es)
|
2012-09-10 |
2018-12-17 |
Principia Biopharma Inc |
Compuestos pirazolopirimidinicos como inhibidores de cinasas.
|
|
CN104995192A
(zh)
|
2012-09-26 |
2015-10-21 |
加利福尼亚大学董事会 |
Ire1的调节
|
|
CN108440571B
(zh)
|
2012-10-22 |
2022-11-04 |
希望之城 |
Etp衍生物
|
|
US9364462B2
(en)
|
2012-10-30 |
2016-06-14 |
The Regents Of The University Of California |
Alpha-1-adrenergic receptor agonist therapy
|
|
CA2900779C
(en)
|
2013-02-11 |
2021-10-26 |
The Regents Of The University Of California |
Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
|
|
US9938263B2
(en)
|
2013-03-12 |
2018-04-10 |
The General Hospital Corporation |
Gamma-secretase modulators
|
|
WO2014143591A1
(en)
|
2013-03-12 |
2014-09-18 |
Allergan, Inc. |
Inhibition of neovascularization by simultaneous inhibition of prostanoid ip and ep4 receptors
|
|
WO2014143592A1
(en)
|
2013-03-12 |
2014-09-18 |
Allergan, Inc. |
Inhibition of neovascularization by inhibition of prostanoid ip receptors
|
|
JP6422936B2
(ja)
|
2013-03-14 |
2018-11-14 |
シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ |
５−ブロモ−インジルビン
|
|
CA2903827C
(en)
|
2013-03-14 |
2021-08-10 |
Stefan Oscarson |
Thiosaccharide mucolytic agents
|
|
EP2968270A4
(en)
|
2013-03-14 |
2016-08-17 |
Univ California |
MODULATION OF K2P CHANNELS
|
|
CN105246902B
(zh)
|
2013-03-15 |
2018-05-04 |
加利福尼亚大学董事会 |
无环核苷膦酸二酯
|
|
WO2014143629A1
(en)
|
2013-03-15 |
2014-09-18 |
Allergan, Inc. |
Bimatoprost for enhancement of leptin production
|
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
|
WO2014146111A2
(en)
|
2013-03-15 |
2014-09-18 |
The Regents Of The University Of California |
Analgesic compounds and methods of use
|
|
WO2014144952A2
(en)
|
2013-03-15 |
2014-09-18 |
Peter Walter |
Modulators of the eif2alpha pathway
|
|
EP2968297B1
(en)
|
2013-03-15 |
2018-09-26 |
Verseon Corporation |
Multisubstituted aromatic compounds as serine protease inhibitors
|
|
CA2902431A1
(en)
|
2013-03-15 |
2014-09-25 |
Kevin Michael Short |
Halogenopyrazoles as inhibitors of thrombin
|
|
US8957080B2
(en)
|
2013-04-09 |
2015-02-17 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
EP2999472B1
(en)
|
2013-05-22 |
2020-07-22 |
The Regents of The University of California |
Aurora kinase inhibitors
|
|
US9795691B2
(en)
|
2013-06-24 |
2017-10-24 |
City Of Hope |
Chemically-linked nanoparticles
|
|
AU2014290202B2
(en)
|
2013-07-15 |
2018-11-15 |
Board Of Regents, The University Of Texas System |
Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain
|
|
RS61038B1
(sr)
|
2013-08-19 |
2020-12-31 |
Univ California |
Jedinjenja i metodi za lečenje epileptičnog poremećaja
|
|
CN105979941A
(zh)
|
2013-08-20 |
2016-09-28 |
希望之城 |
用于治疗癌症的hdac8抑制剂
|
|
WO2015031799A1
(en)
|
2013-08-30 |
2015-03-05 |
The Regents Of The University Of California, A California Corporation |
Scintillator nanocrystal-containing compositions and methods for their use
|
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Ｋｒａｓ ｇ１２ｃ之抑制劑
|
|
EP3444251B1
(en)
|
2013-12-11 |
2023-06-07 |
Biogen MA Inc. |
Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
|
|
CA2932608C
(en)
|
2013-12-11 |
2023-02-14 |
Biogen Ma Inc. |
Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
|
|
JP6491214B2
(ja)
|
2013-12-23 |
2019-03-27 |
メモリアル スローン ケタリング キャンサー センター |
放射性標識のための方法および試薬
|
|
PT2898888T
(pt)
|
2014-01-22 |
2019-07-16 |
Visufarma B V |
Composição que compreende iota-carragenina contra conjuntivite viral
|
|
WO2015116856A2
(en)
|
2014-01-29 |
2015-08-06 |
City Of Hope |
Farnesoid x receptor antagonists
|
|
EP3104706B1
(en)
|
2014-02-11 |
2022-03-23 |
Mitokinin, Inc. |
Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
|
|
EP3104857A4
(en)
|
2014-02-14 |
2017-10-11 |
The Regents of The University of California |
Cyclic peroxides as prodrugs for selective delivery of agents
|
|
TR201902864T4
(tr)
|
2014-02-20 |
2019-03-21 |
Allergan Inc |
Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanımı ile azaltılmış merkezi korneal kalınlaşma.
|
|
US10092569B2
(en)
|
2014-02-21 |
2018-10-09 |
Principia Biopharma Inc. |
Salts and solid form of a BTK inhibitor
|
|
US20150259288A1
(en)
|
2014-03-14 |
2015-09-17 |
City Of Hope |
5-bromo-indirubins
|
|
JP6473461B2
(ja)
|
2014-03-26 |
2019-02-20 |
シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ |
Ｂｒｃａ１欠損癌または耐性癌の治療
|
|
ES2908240T3
(es)
|
2014-04-07 |
2022-04-28 |
Univ California |
Inhibidores de la enzima amida hidrolasa de ácidos grasos (FAAH) con biodisponibilidad oral mejorada y su uso como medicamentos
|
|
EP3143013B1
(en)
|
2014-05-13 |
2019-12-18 |
Memorial Sloan Kettering Cancer Center |
Hsp70 modulators and methods for making and using the same
|
|
US10166246B2
(en)
|
2014-05-27 |
2019-01-01 |
City Of Hope |
TGR5 agonist complexes for treating diabetes and cancer
|
|
WO2016004383A1
(en)
|
2014-07-03 |
2016-01-07 |
City Of Hope |
Tumor-selective ctla-4 antagonists
|
|
WO2016018917A2
(en)
|
2014-07-28 |
2016-02-04 |
The Regents Of The University Of Califoria |
Compositions and methods of making polymerized nucleic acids
|
|
US10980744B2
(en)
|
2014-08-08 |
2021-04-20 |
The Regents Of The University Of California |
High density peptide polymers
|
|
WO2016040806A1
(en)
|
2014-09-11 |
2016-03-17 |
The Regents Of The University Of California |
mTORC1 INHIBITORS
|
|
EA036391B1
(ru)
|
2014-09-15 |
2020-11-05 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния |
Нуклеотидные аналоги
|
|
JP2017528486A
(ja)
|
2014-09-17 |
2017-09-28 |
ヴァーセオン コーポレイション |
セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
WO2016049568A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Methods and compositions for inhibition of ras
|
|
JP2017528498A
(ja)
|
2014-09-25 |
2017-09-28 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター
|
|
EP3201192B1
(en)
|
2014-10-02 |
2019-08-21 |
Allergan, Inc. |
Ester prodrugs of gamma-lactams and their use
|
|
SG11201704808VA
(en)
|
2014-12-18 |
2017-07-28 |
Principia Biopharma Inc |
Treatment of pemphigus
|
|
EP3244907B1
(en)
|
2015-01-13 |
2020-02-19 |
City of Hope |
Ctla4-binding protein peptide-linker masks
|
|
MX2017009272A
(es)
|
2015-01-16 |
2018-04-11 |
|
Anticuerpos que penetran en células.
|
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
|
US9522918B2
(en)
|
2015-02-12 |
2016-12-20 |
Neonc Technologies, Inc. |
Pharmaceutical compositions comprising perillyl alcohol derivatives
|
|
EA201791882A1
(ru)
|
2015-02-25 |
2018-02-28 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа |
Агонисты 5ht для лечения нарушений
|
|
PL3261639T3
(pl)
|
2015-02-27 |
2022-12-19 |
Verseon International Corporation |
Podstawione związki pirazolowe jako inhibitory proteazy serynowej
|
|
EA039121B1
(ru)
|
2015-02-27 |
2021-12-07 |
Куртана Фармасьютикалс, Инк. |
ИНГИБИРОВАНИЕ АКТИВНОСТИ Olig2
|
|
US11072592B2
(en)
|
2015-02-27 |
2021-07-27 |
The Regents Of The University Of California |
Small molecules that enable cartilage rejuvenation
|
|
CN107614523A
(zh)
|
2015-03-30 |
2018-01-19 |
希望之城 |
机械互锁复合物
|
|
CN107849022A
(zh)
|
2015-04-10 |
2018-03-27 |
亚瑞克西斯制药公司 |
取代的喹唑啉化合物和其使用方法
|
|
ES2856880T3
(es)
|
2015-04-15 |
2021-09-28 |
Araxes Pharma Llc |
Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
|
|
CA2982890C
(en)
|
2015-04-17 |
2023-08-22 |
Ludwig Institute For Cancer Research Ltd |
Plk4 inhibitors
|
|
EP3286214B1
(en)
|
2015-04-24 |
2023-12-06 |
The Regents of the University of California |
Modulators of ror1-ror2 binding
|
|
EP3294764B1
(en)
|
2015-05-15 |
2020-12-30 |
City of Hope |
Chimeric antigen receptor compositions
|
|
US10787664B2
(en)
|
2015-05-26 |
2020-09-29 |
City Of Hope |
Compounds of chemically modified oligonucleotides and methods of use thereof
|
|
MA42510A
(fr)
|
2015-06-10 |
2018-06-06 |
Biogen Ma Inc |
Formes et compositions d'inhibiteurs biaryles de la tyrosine kinase de bruton
|
|
WO2016201169A1
(en)
|
2015-06-10 |
2016-12-15 |
City Of Hope |
Compositions of and methods of treatment with zwitterionic polysaccharide
|
|
US20180305350A1
(en)
|
2015-06-24 |
2018-10-25 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
CN114224907A
(zh)
|
2015-07-02 |
2022-03-25 |
希望之城 |
包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
US10065946B2
(en)
|
2015-08-04 |
2018-09-04 |
Rigel Pharmaceuticals, Inc. |
Benzazole compounds and methods for making and using the compounds
|
|
CN108135958B
(zh)
|
2015-08-06 |
2022-03-04 |
希望之城 |
细胞穿透蛋白-抗体缀合物及其使用方法
|
|
WO2017040693A1
(en)
|
2015-08-31 |
2017-03-09 |
The Regents Of The University Of California |
Broad spectrum antiviral compounds and uses thereof
|
|
US11124483B2
(en)
|
2015-09-02 |
2021-09-21 |
The Regents Of The University Of California |
HER3 ligands and uses thereof
|
|
US10428048B2
(en)
|
2015-09-04 |
2019-10-01 |
City Of Hope |
Androgen receptor antagonists
|
|
CN108430978B
(zh)
|
2015-09-25 |
2022-11-22 |
路德维格癌症研究所有限责任公司 |
3-羟基-喹唑啉-2,4-二酮衍生物及其作为核酸酶调节剂的用途
|
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10730867B2
(en)
|
2015-09-28 |
2020-08-04 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
EP3356351A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356359B1
(en)
|
2015-09-28 |
2021-10-20 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
US10875842B2
(en)
|
2015-09-28 |
2020-12-29 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3364984B1
(en)
|
2015-10-15 |
2021-11-17 |
City of Hope |
Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
|
|
WO2017070256A2
(en)
|
2015-10-19 |
2017-04-27 |
Araxes Pharma Llc |
Method for screening inhibitors of ras
|
|
EP3364956A4
(en)
|
2015-10-23 |
2019-05-01 |
ERX Pharmaceuticals, Inc. |
ANALOG OF CELASTROL
|
|
EP3364971B1
(en)
|
2015-10-23 |
2020-06-17 |
Sunesis Pharmaceuticals, Inc. |
Heterocyclic pdk1 inhibitors for use to treat cancer
|
|
US11058700B2
(en)
|
2015-10-28 |
2021-07-13 |
City Of Hope |
Macrocyclic lactones and uses thereof as modulators of purinergic receptors
|
|
EA038635B9
(ru)
|
2015-11-16 |
2021-10-26 |
Араксис Фарма Ллк |
2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
|
|
WO2017100546A1
(en)
|
2015-12-09 |
2017-06-15 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
|
CN112274649A
(zh)
|
2015-12-10 |
2021-01-29 |
希望之城 |
细胞穿透花青偶联抗体
|
|
CN115710233A
(zh)
|
2015-12-24 |
2023-02-24 |
加利福尼亚大学董事会 |
Cftr调节剂及其使用方法
|
|
RU2730855C2
(ru)
|
2015-12-24 |
2020-08-26 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа |
Кфтр регуляторы и способы их применения
|
|
CN108779094B
(zh)
|
2015-12-30 |
2021-11-16 |
Nqp 1598公司 |
金属酶抑制剂化合物
|
|
CN108697690B
(zh)
|
2016-01-05 |
2022-01-14 |
加利福尼亚大学董事会 |
苯并噻唑两亲物
|
|
US10519442B2
(en)
|
2016-02-11 |
2019-12-31 |
City Of Hope |
Twist signaling inhibitor compositions and methods of using the same
|
|
BR112018068798A2
(pt)
|
2016-03-17 |
2019-01-22 |
Univ California |
composições e métodos para tratamento de doenças parasíticas
|
|
WO2017172979A1
(en)
|
2016-03-30 |
2017-10-05 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
|
ES2886935T3
(es)
|
2016-04-25 |
2021-12-21 |
Forma Therapeutics Inc |
Inhibidores de FASN para su uso en el tratamiento de esteatohepatitis no alcohólica
|
|
WO2017190107A1
(en)
|
2016-04-29 |
2017-11-02 |
Board Of Regents, The University Of Texas System |
Sigma receptor binders
|
|
TWI844006B
(zh)
|
2016-05-05 |
2024-06-01 |
美商嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
|
TW201808914A
(zh)
|
2016-05-05 |
2018-03-16 |
嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
|
DK3578562T3
(da)
|
2016-05-12 |
2021-07-12 |
Anacor Pharmaceuticals Inc |
L-valinatamidbenzoxaborolderivater til behandling af parasitiske sygdomme
|
|
EP3463342B1
(en)
|
2016-05-26 |
2023-09-06 |
The Regents of The University of California |
Estrogen receptor modulator combinations
|
|
JP7065840B2
(ja)
|
2016-06-27 |
2022-05-12 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
２，４－ジアミノ－ピリミジン化合物ならびに該化合物の作製法および使用法
|
|
IL263815B
(en)
|
2016-06-29 |
2022-07-01 |
Principia Biopharma Inc |
Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
|
US11045493B2
(en)
|
2016-07-11 |
2021-06-29 |
The Regents Of The University Of California |
Synthetic melanin nanoparticles and uses thereof
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
BR112019001158A2
(pt)
|
2016-07-21 |
2019-04-30 |
Biogen Ma, Inc. |
formas de succinato e composições de inibidores da tirosina quinase de bruton
|
|
EP3490565B1
(en)
|
2016-07-29 |
2022-06-08 |
RAPT Therapeutics, Inc. |
Azetidine derivatives as chemokine receptor modulators and uses thereof
|
|
US11542261B2
(en)
|
2016-08-17 |
2023-01-03 |
Children's Hospital Medical Center |
Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
|
|
US11254667B2
(en)
|
2016-08-17 |
2022-02-22 |
Children's Hospital Medical Center |
Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors
|
|
WO2018039612A1
(en)
|
2016-08-26 |
2018-03-01 |
The Regents Of The University Of California |
Compositions and methods for promoting hair growth with mpc1 inhibitors
|
|
US11780895B2
(en)
|
2016-09-13 |
2023-10-10 |
The Jackson Laboratory |
Targeted DNA demethylation and methylation
|
|
JP7088912B2
(ja)
|
2016-09-15 |
2022-06-21 |
シティ・オブ・ホープ |
ジチオｅｔｐ誘導体
|
|
US10849955B2
(en)
|
2016-09-28 |
2020-12-01 |
City Of Hope |
Methods of treating pancreatic cancer using GPCR antagonists
|
|
US10280172B2
(en)
|
2016-09-29 |
2019-05-07 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2018068017A1
(en)
|
2016-10-07 |
2018-04-12 |
Araxes Pharma Llc |
Heterocyclic compounds as inhibitors of ras and methods of use thereof
|
|
PT3532470T
(pt)
|
2016-10-26 |
2023-02-28 |
Rigel Pharmaceuticals Inc |
Derivados de oxazol para uso como inibidores de irak e método para a sua preparação
|
|
CA3040526A1
(en)
|
2016-10-26 |
2018-05-03 |
Rigel Pharmaceuticals, Inc. |
Pyrazole amide compounds as irak inhibitors
|
|
US10646540B2
(en)
|
2016-11-18 |
2020-05-12 |
City Of Hope |
Peptide inhibitors of twist
|
|
JP7144411B2
(ja)
|
2016-11-30 |
2022-09-29 |
ネオンク テクノロジーズ インク． |
ペリリルアルコール－３－ブロモピルベート複合体及びがんの治療方法
|
|
BR112019012263A2
(pt)
|
2016-12-15 |
2020-01-28 |
Univ California |
composições e métodos para tratar câncer
|
|
ES2967119T3
(es)
|
2016-12-29 |
2024-04-26 |
Ji Xing Pharmaceuticals Hong Kong Ltd |
Compuestos inhibidores de metaloenzimas
|
|
WO2018125799A2
(en)
|
2016-12-29 |
2018-07-05 |
Viamet Pharmaceuticals (Bermuda), Ltd. |
Metalloenzyme inhibitor compounds
|
|
US11274093B2
(en)
|
2017-01-26 |
2022-03-15 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
EP3573970A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
|
US11059819B2
(en)
|
2017-01-26 |
2021-07-13 |
Janssen Biotech, Inc. |
Fused hetero-hetero bicyclic compounds and methods of use thereof
|
|
WO2018140513A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
JP2020521741A
(ja)
|
2017-05-25 |
2020-07-27 |
アラクセス ファーマ エルエルシー |
がんの処置のための化合物およびその使用の方法
|
|
WO2018218070A2
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Covalent inhibitors of kras
|
|
WO2018218069A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant kras, hras or nras
|
|
CA3067695A1
(en)
|
2017-06-21 |
2018-12-27 |
Mitokinin, Inc. |
Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
|
|
CN111032642B
(zh)
|
2017-06-29 |
2023-07-18 |
里格尔药品股份有限公司 |
激酶抑制剂及制造和使用方法
|
|
US11554178B2
(en)
|
2017-06-30 |
2023-01-17 |
City Of Hope |
Compositions and methods of modulating macrophage activity
|
|
US11389460B2
(en)
|
2017-09-15 |
2022-07-19 |
City Of Hope |
Methods and compositions for treating endometrial cancer
|
|
MA50664A
(fr)
|
2017-09-29 |
2020-08-05 |
Genentech Inc |
Complexes d'antibiotiques peptidiques et leurs méthodes d'utilisation
|
|
WO2019067015A1
(en)
|
2017-09-29 |
2019-04-04 |
City Of Hope |
RECEPTORS OF CHIMERIC ANTIGENS AND BISPECIFIC ANTIBODIES FOR THE TREATMENT OF COAT CELL LYMPHOMA
|
|
WO2019070917A1
(en)
|
2017-10-03 |
2019-04-11 |
The Schepens Eye Research Institute, Inc. |
COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE DEGENERATION OF RETINAL PIGMENT EPITHELIUM AND METHODS USING SAME
|
|
TW201927787A
(zh)
|
2017-10-10 |
2019-07-16 |
美商錫羅斯製藥公司 |
吡咯並三嗪化合物及抑制ｔａｍ激酶之方法
|
|
US11618780B2
(en)
|
2017-10-20 |
2023-04-04 |
City Of Hope |
Composition and method for activating latent human immunodeficiency virus (HIV)
|
|
AU2018360850A1
(en)
|
2017-11-02 |
2020-06-11 |
Abbvie Inc. |
Modulators of the integrated stress pathway
|
|
UY37958A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
|
WO2019090090A1
(en)
|
2017-11-02 |
2019-05-09 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
|
BR112020008825A2
(pt)
|
2017-11-02 |
2020-10-20 |
Calico Life Sciences Llc |
moduladores da via de estresse integrada
|
|
UY37957A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
|
UY37956A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
|
BR112020008817B8
(pt)
|
2017-11-02 |
2023-10-03 |
Abbvie Inc |
Compostos moduladores da via de estresse integrada
|
|
MX2020004537A
(es)
|
2017-11-02 |
2020-10-05 |
Calico Life Sciences Llc |
Moduladores de la vía integrada del estrés.
|
|
AU2018358160B2
(en)
|
2017-11-02 |
2023-03-16 |
Abbvie Inc. |
Modulators of the integrated stress pathway
|
|
CA3081750A1
(en)
|
2017-11-06 |
2019-05-09 |
Rapt Therapeutics, Inc. |
Anticancer agents
|
|
US20210292410A1
(en)
|
2017-12-07 |
2021-09-23 |
Morphosys Ag |
Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
|
|
BR112020011162A2
(pt)
|
2017-12-07 |
2020-11-17 |
Amplyx Pharmaceuticals, Inc. |
agentes antifúngicos derivados de piridina substituída por heterociclo
|
|
WO2019126037A1
(en)
|
2017-12-19 |
2019-06-27 |
City Of Hope |
Modified tracrrnas grnas, and uses thereof
|
|
EP3740207A4
(en)
|
2018-01-16 |
2021-10-13 |
Syros Pharmaceuticals, Inc. |
CYCLINE-DEPENDENT KINASE 7 (CDK7) INHIBITORS
|
|
CA3088529A1
(en)
|
2018-01-16 |
2019-07-25 |
Syros Pharmaceuticals, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
IL276295B2
(en)
|
2018-01-26 |
2024-02-01 |
Rapt Therapeutics Inc |
Modulators of chemokine receptors and their uses
|
|
WO2019157195A1
(en)
|
2018-02-08 |
2019-08-15 |
Neonc Technologies, Inc |
Methods of permeabilizing the blood brain barrier
|
|
CA3093802A1
(en)
|
2018-03-13 |
2019-09-19 |
Shire Human Genetic Therapies, Inc. |
Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
|
|
MX2020011344A
(es)
|
2018-04-27 |
2021-02-09 |
Spruce Biosciences Inc |
Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.
|
|
IL312291A
(en)
|
2018-05-01 |
2024-06-01 |
Revolution Medicines Inc |
C-26-linked rapamycin analogs as MTOR inhibitors
|
|
CN118978535A
(zh)
|
2018-05-01 |
2024-11-19 |
锐新医药公司 |
作为mTOR抑制剂的C40-、C28-及C-32连接的雷帕霉素类似物
|
|
US10975064B2
(en)
|
2018-05-03 |
2021-04-13 |
Rigel Pharmaceuticals, Inc. |
RIP1 inhibitory compounds and methods for making and using the same
|
|
EP3788044B1
(en)
|
2018-05-03 |
2023-08-09 |
Rigel Pharmaceuticals, Inc. |
Rip1 inhibitory compounds and methods for making and using the same
|
|
US11931345B2
(en)
|
2018-05-04 |
2024-03-19 |
Cirius Therapeutics, Inc. |
Thiazolidinedione analogs for the treatment of NAFLD and metabolic diseases
|
|
JP2021527051A
(ja)
|
2018-06-05 |
2021-10-11 |
ラプト・セラピューティクス・インコーポレイテッド |
ピラゾロ−ピリミジン−アミノ−シクロアルキル化合物及びその治療的使用
|
|
AR125425A1
(es)
|
2018-06-21 |
2023-07-19 |
Calico Life Sciences Llc |
Inhibidores de proteina tirosina fosfatasa y sus metodos de uso
|
|
CA3104653A1
(en)
|
2018-06-25 |
2020-01-02 |
Amplyx Pharmaceuticals, Inc. |
Pyridine derivatives substituted by heterocyclic ring and amino group
|
|
WO2020028706A1
(en)
|
2018-08-01 |
2020-02-06 |
Araxes Pharma Llc |
Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
|
|
US20210221864A1
(en)
|
2018-08-24 |
2021-07-22 |
City Of Hope |
Masked cytokine conjugates
|
|
US12187762B2
(en)
|
2018-09-10 |
2025-01-07 |
The Regents Of The University Of California |
Dithiolsaccharide mucolytic agents and uses thereof
|
|
TWI832295B
(zh)
|
2018-10-11 |
2024-02-11 |
美商嘉來克生命科學有限責任公司 |
整合應激路徑之前藥調節劑
|
|
KR20210090173A
(ko)
|
2018-11-01 |
2021-07-19 |
링크 파마슈티컬스 컴퍼니 리미티드 |
트리사이클릭 야누스 키나제 1 억제제 및 이의 조성물 및 방법
|
|
US20220000880A1
(en)
|
2018-11-01 |
2022-01-06 |
Rigel Pharmaceuticals, Inc. |
Method and composition embodiments for treating acute myeloid leukemia
|
|
WO2020186199A1
(en)
|
2019-03-14 |
2020-09-17 |
Calico Life Sciences Llc |
Protein tyrosine phosphatase inhibitors and methods of use thereof
|
|
AR118837A1
(es)
|
2019-04-30 |
2021-11-03 |
Calico Life Sciences Llc |
Moduladores de la vía integrada del estrés
|
|
CA3140046A1
(en)
|
2019-05-15 |
2020-11-19 |
Bexson Biomedical, Inc. |
Ketamine formulation for subcutaneous injection
|
|
US20200377518A1
(en)
|
2019-05-29 |
2020-12-03 |
Rigel Pharmaceuticals, Inc. |
Method of preventing and treating thrombosis
|
|
US20220267753A1
(en)
|
2019-06-14 |
2022-08-25 |
Children's Hospital Medical Center |
Rational therapeutic targeting of oncogenic immune signaling states in myeloid malignancies via the ubiquitin conjugating enzyme ube2n
|
|
WO2021026451A1
(en)
|
2019-08-08 |
2021-02-11 |
Rigel Pharmaceuticals, Inc. |
Compounds and method for treating cytokine release syndrome
|
|
CN114286679A
(zh)
|
2019-08-14 |
2022-04-05 |
里格尔药品股份有限公司 |
阻断或改善细胞因子释放综合征的方法
|
|
US11370787B2
(en)
|
2019-08-30 |
2022-06-28 |
Rigel Pharmaceuticals, Inc. |
Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations
|
|
JP7493586B2
(ja)
|
2019-09-06 |
2024-05-31 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法
|
|
KR20220042204A
(ko)
|
2019-09-06 |
2022-04-04 |
리겔 파마슈티칼스, 인크. |
Rip1 억제 화합물 및 그를 제조 및 사용하는 방법
|
|
BR112022004475A2
(pt)
|
2019-09-18 |
2022-05-31 |
Novartis Ag |
Proteínas de fusão nkg2d e usos das mesmas
|
|
JP2022549601A
(ja)
|
2019-09-18 |
2022-11-28 |
武田薬品工業株式会社 |
ヘテロアリール血漿カリクレインインヒビター
|
|
PL4031547T3
(pl)
|
2019-09-18 |
2024-10-07 |
Takeda Pharmaceutical Company Limited |
Inhibitory kalikreiny osoczowej i ich zastosowania
|
|
CA3154257A1
(en)
|
2019-10-14 |
2021-04-22 |
Principia Biopharma Inc. |
Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
|
EP4055021A1
(en)
|
2019-11-07 |
2022-09-14 |
Rigel Pharmaceuticals, Inc. |
Heterocyclic rip1 inhibitory compounds
|
|
JP2023501584A
(ja)
|
2019-11-13 |
2023-01-18 |
ラプト・セラピューティクス・インコーポレイテッド |
Ｃ－ｃケモカイン受容体４型アンタゴニストの結晶形態、およびその使用
|
|
CA3162069A1
(en)
|
2019-12-18 |
2021-06-24 |
Elliot P. Farney |
Protein tyrosine phosphatase inhibitors and methods of use thereof
|
|
IL312785A
(en)
|
2020-05-19 |
2024-07-01 |
Cybin Irl Ltd |
Denatured Tryptamine Derivatives and Methods of Use
|
|
WO2022038170A1
(en)
|
2020-08-18 |
2022-02-24 |
Cybin Irl Limited |
Therapeutic phenethylamine compositions and methods of use
|
|
MX2023005056A
(es)
|
2020-11-02 |
2023-07-24 |
Trethera Corp |
Formas cristalinas de un inhibidor de cinasa de desoxicitidina y sus usos.
|
|
JP2023551145A
(ja)
|
2020-11-18 |
2023-12-07 |
ベクソン バイオメディカル，インク． |
医薬化合物の錯化剤塩製剤
|
|
US20240058344A1
(en)
|
2020-12-18 |
2024-02-22 |
Cornell University |
Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
|
|
WO2022187303A1
(en)
|
2021-03-03 |
2022-09-09 |
Rigel Pharmaceuticals, Inc. |
A method for treating a disease or condition using a pyrazole compound or formulation thereof
|
|
AR125587A1
(es)
|
2021-03-11 |
2023-08-02 |
Rigel Pharmaceuticals Inc |
Inhibidores heterocíclicos de la quinasa de rip1
|
|
US11918582B2
(en)
|
2021-03-15 |
2024-03-05 |
Rapt Therapeutics, Inc. |
Pyrazole pyrimidine compounds and uses thereof
|
|
WO2022197756A1
(en)
|
2021-03-17 |
2022-09-22 |
Shire Human Genetic Therapies, Inc. |
Plasma kallikrein inhibitors
|
|
EP4308230A1
(en)
|
2021-03-17 |
2024-01-24 |
Takeda Pharmaceutical Company Limited |
Heteroaryl inhibitors of plasma kallikrein
|
|
CN117396469A
(zh)
|
2021-03-17 |
2024-01-12 |
武田药品工业株式会社 |
血浆激肽释放酶的抑制剂
|
|
JP2024510504A
(ja)
|
2021-03-17 |
2024-03-07 |
武田薬品工業株式会社 |
血漿カリクレインの多環式インヒビター
|
|
EP4308227A1
(en)
|
2021-03-17 |
2024-01-24 |
Takeda Pharmaceutical Company Limited |
Imidazopyridinyl inhibitors of plasma kallikrein
|
|
AU2023222126A1
(en)
|
2022-02-15 |
2024-08-08 |
Cybin Irl Limited |
Phenethylamine derivatives, compositions, and methods of use
|
|
WO2023156450A1
(en)
|
2022-02-15 |
2023-08-24 |
Cybin Irl Limited |
Therapeutic phenethylamine compositions and methods of use
|
|
US20230303555A1
(en)
|
2022-03-23 |
2023-09-28 |
Rigel Pharmaceuticals, Inc. |
Pyrimid-2-yl-pyrazole compounds as irak inhibitors
|
|
US20230312568A1
(en)
|
2022-03-31 |
2023-10-05 |
Rigel Pharmaceuticals, Inc. |
Tricyclic irak inhibitors
|
|
US12240837B2
(en)
|
2022-04-06 |
2025-03-04 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|
|
CN114504550B
(zh)
*
|
2022-04-18 |
2022-08-19 |
中山大学中山眼科中心 |
一种包含甲硝唑的眼用凝胶及其制备方法
|
|
WO2023230577A1
(en)
|
2022-05-25 |
2023-11-30 |
Revolution Medicines, Inc. |
Methods of treating cancer with an mtor inhibitor
|
|
US20250034115A1
(en)
|
2023-07-12 |
2025-01-30 |
Rapt Therapeutics, Inc. |
Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof
|
|
WO2025015189A1
(en)
|
2023-07-13 |
2025-01-16 |
Comanche Biopharma Corp. |
Formulations of nucleic acid compounds and uses thereof
|
|
WO2025027529A1
(en)
|
2023-07-31 |
2025-02-06 |
Advesya |
Anti-il-1rap antibody drug conjugates and methods of use thereof
|